Neuren Pharmaceuticals Full Year 2023 Earnings: EPS Misses Expectations

Neuren Pharmaceuticals (ASX:NEU) Full Year 2023 Results

Key Financial Results

• Revenue: AU$240.1m (up by AU$224.6m from FY 2022).
• Net income: AU$157.1m (up by AU$156.9m from FY 2022).
• Profit margin: 65% (up from 1.2% in FY 2022). The increase in margin was driven by higher revenue.
• EPS: AU$1.24 (up from AU$0.001 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Neuren Pharmaceuticals EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 11%.

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Pharmaceuticals industry in Australia.

Performance of the Australian Pharmaceuticals industry.

The company's shares are down 5.0% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on Neuren Pharmaceuticals' balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.